Data / Drug companies / Advanced Rx of Tennessee, LLC
Advanced Rx of Tennessee, LLC: 534 products in the FDA NDC directory, labeler code 80425
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Advanced Rx of Tennessee, LLC (labeler code 80425) lists 534 products in the FDA National Drug Code Directory, covering 169 finished drugs by generic name. By type: 509 prescription drugs, 19 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 11, 2026.
The request: Watch Advanced Rx of Tennessee, LLC (FDA labeler code 80425): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 80425
- Products in commercial distribution
- 534
- Packages
- 1,279
- Finished drugs by generic name
- 169
- Prescription products
- 509
- Over the counter products
- 19
- Controlled substance products
- Schedule III 8, Schedule IV 49, Schedule V 25
- Started marketing in the last 12 months
- 37
- Products with a marketing end date set
- 3
- Earliest marketing start
- December 10, 1986
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 471 | 88.2% |
| Other unapproved drugs | 25 | 4.7% |
| Authorized generics (NDA) | 16 | 3% |
| Over the counter monograph drugs | 15 | 2.8% |
| Bulk ingredients for compounding | 4 | 0.7% |
| Drugs for further processing | 2 | 0.4% |
| New drug applications (NDA) | 1 | 0.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 509 | 95.3% |
| Over the counter drugs | 19 | 3.6% |
| Bulk ingredients | 4 | 0.7% |
| Drugs for further processing | 2 | 0.4% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 171 | 32% |
| Tablet, film coated | 97 | 18.2% |
| Capsule | 83 | 15.5% |
| Capsule, delayed release | 20 | 3.7% |
| Tablet, delayed release | 18 | 3.4% |
| Kit | 16 | 3% |
| Tablet, coated | 14 | 2.6% |
| Capsule, extended release | 14 | 2.6% |
| Tablet, extended release | 13 | 2.4% |
| Ointment | 13 | 2.4% |
| Patch | 12 | 2.2% |
| Solution | 10 | 1.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Gabapentin | 80425-0595 | Capsule | Generic drugs (ANDA) | September 11, 2026 |
| Lidocaine | 80425-0594 | Ointment | Generic drugs (ANDA) | September 10, 2026 |
| Salicor | 80425-0592 | Patch | Other unapproved drugs | August 6, 2026 |
| Ramelteon | 80425-0593 | Tablet | Generic drugs (ANDA) | July 27, 2026 |
| Metformin Hydrochloride | 80425-0591 | Tablet, film coated | Generic drugs (ANDA) | July 10, 2026 |
| Hydroxyzine hydrochloride | 80425-0590 | Tablet, film coated | Generic drugs (ANDA) | July 10, 2026 |
| Famotidine | 80425-0589 | Tablet, film coated | Generic drugs (ANDA) | July 10, 2026 |
| Tramadol Hydrochloride | 80425-0588 | Tablet | Generic drugs (ANDA) | June 26, 2026 |
| Ibuprofen and Famotidine | 80425-0587 | Tablet | Generic drugs (ANDA) | June 18, 2026 |
| Meloxicam | 80425-0586 | Tablet | Generic drugs (ANDA) | June 18, 2026 |
| Meloxicam | 80425-0585 | Tablet | Generic drugs (ANDA) | June 18, 2026 |
| Meloxicam | 80425-0584 | Tablet | Generic drugs (ANDA) | June 18, 2026 |
| Propranolol Hydrochloride | 80425-0583 | Tablet | Generic drugs (ANDA) | June 12, 2026 |
| Lidocaine and Menthol | 80425-0560 | Patch | Over the counter monograph drugs | June 12, 2026 |
| LidoPro | 80425-0582 | Patch | Over the counter monograph drugs | April 17, 2026 |
| Metaxalone | 80425-0580 | Tablet | Generic drugs (ANDA) | April 17, 2026 |
| Venlafaxine Hydrochloride | 80425-0581 | Capsule, extended release | Generic drugs (ANDA) | April 9, 2026 |
| Methocarbamol | 80425-0578 | Tablet, coated | Generic drugs (ANDA) | March 13, 2026 |
| Methocarbamol | 80425-0577 | Tablet | Generic drugs (ANDA) | February 18, 2026 |
| Topiramate | 80425-0576 | Tablet, film coated | Generic drugs (ANDA) | February 18, 2026 |
| Naproxen Sodium | 80425-0574 | Tablet | Generic drugs (ANDA) | February 4, 2026 |
| Lidothol ES | 80425-0561 | System | Other unapproved drugs | February 2, 2026 |
| Marlido Kit | 80425-0573 | Kit | Other unapproved drugs | January 30, 2026 |
| Toronova II SUIK | 80425-0572 | Injection, solution | Other unapproved drugs | January 23, 2026 |
| Cefuroxime axetil | 80425-0571 | Tablet, film coated | Generic drugs (ANDA) | January 16, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.